1. Szebeni, J., Wassef NM, Hartman KR, Rudolph AS. & Alving CR. (1997) Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 37:150-9

2. Szebeni, J. Muggia FM, & Alving CR.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. (1998) J.  Natl. Cancer Inst. 90:300-6

3. Szebeni, J. Fontana, JL, Wassef, NM, Mongan, PD, Morse, DS, Dobbins, DE, Stahl, GL, Bünger R & Alving, CR. (1999) Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs: A Model for Pseudo-Allergic Cardiopulmonary Reactions to Liposomes: Role of Complement and Inhibition by Soluble CR1 and Anti-C5a Antibody.  Circulation, 99:2302-2309.

4. Szebeni J, Baranyi B, Savay S, Bodo M, Morse DS, Basta M, Stahl GL, Bunger R, Alving CR. (2000) Liposome-induced pulmonary hypertension in pigs: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 279: H1319-H1328

5. Szebeni, J., Baranyi L, Savay S, Lutz HU, Jelezarova E, Bunger R, Alving CR. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). (2000)  J. Liposome Res. 10:347-360

6. Szebeni, J., Alving, C.R., Savay, S., Barenholz,Y., Priev, A., Danino, D., Talmon, Y. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. (2001) Int. Immunopharmacol. 1, 721-35

7. Szebeni, J., Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. (2001) Crit. Rev. Ther. Drug Carr. Syst. 18:567-606

8. Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bodo, M., Bunger, R., Alving, C.R. The Interaction of Liposomes with the Complement System: In Vitro and In Vivo Assays. Methods. Enzymol.  (2003) 373:136-54

9. Moghimi, S. M. and Szebeni, J. Stealth Liposomes and Long Circulating Nanoparticles: Circulation Profiles, Protein-Binding Properties and Activation of Complement in Blood.  Prog Lipid Res. (2003) 42:463-78

10.  Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N.M., Alving, C.R., Muggia, F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.  Annals Oncol. (2003) 14:1430-7.

11.  Szebeni J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005;216:106-21

12.  Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Milosevits, J., Alving, C.R., Bunger, R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. 2006;290:H1050-8

Home | Company Profile | Background | Services | References | Contact Us